61 results about "Trigeminal nerve" patented technology

A soaking device and methods of using are used to cool and / or to heat a face of a person for a purpose of inducing a desired and / or intended outcome in that person. The cooling and / or the heating of the face may be sufficient to induce the desired and / or the intended outcome in that person. The desired and / or intended outcome may relate to: release of at least one type of neurotransmitter; trigeminal nerve stimulation; (indirect) vagus nerve stimulation; transdermal drug delivery; bypass of the blood-brain-barrier (BBB); aesthetic medicine; cardiovascular; dermatological; ears, nose, and throat (otolaryngological); ophthalmological; neurological; psychological; endocrinological; and / or rheumatological benefits to that person. At least one step of the method may include receiving at least some of the face within an immersion-liquid for at least a minimum amount of time while the immersion-liquid is within a temperature-range and while the immersion-liquid is within the soaking device.

The invention belongs to the technical field of medical biological materials, and particularly relates to a repair material for trigeminal nerve injury as well as a preparation method and application of the repair material. The repairing material is prepared from the following raw materials in parts by mass: 0.5 to 5 parts of nervous tissue acellular matrix micro powder, 0.5 to 5 parts of oxidized sodium alginate, 0.005 to 0.02 part of calcium dobesilate, 0.4 to 1 part of Ca-EDTA (Ethylene Diamine Tetraacetic Acid) and 0.4 to 1 part of D-glucolactone. The repairing material is directly injected to the exposed nerve part, damaged nerves are wrapped, the protection effect is achieved, external environment irritation is prevented, the components of the repairing material have the nerve nourishing effect, repairing of the damaged nerves can be promoted, permanent injury of trigeminal nerves is avoided, the duration time of related symptoms is shortened, and the repairing material has a good application prospect. Therefore, the method has good practical application value.

The invention discloses trigeminal nerve electrical stimulation equipment and a use method thereof, and relates to the technical field of nerve treatment.The trigeminal nerve electrical stimulation equipment comprises an electrical stimulator and a remote controller, the electrical stimulator is fixedly connected with a connector, a wire is inserted into the connecting end of the connector, the connector fixes the wire, and the connector is connected with the remote controller. The outer side of the tail end of the wire is fixedly connected with a plurality of electrode slices, the outer side of the wire is fixedly connected with a plurality of anchor points located at the front ends of the electrode slices, and the remote controller is in wireless communication connection with the electrical stimulator. The device can be buried in the body of a patient for a long time, so that the effect of inhibiting the pain of the patient can be guaranteed, multiple operations for inhibiting the pain of the patient are not needed after one operation when the pain fed back by the patient still exists, and the damage to the body of the patient is reduced.

The invention discloses a flavor modifier, atomized essence and an aerosol generating device, and relates to the technical field of essence. According to the technical scheme, the flavor modifier comprises an active agent, a compound containing a phenolic hydroxyl group and-O-beta-D-glucosidic bond or a compound containing an alcoholic hydroxyl group and-O-beta-D-glucosidic bond is selected as the active agent, and the flavor modifier can be weakly combined with a Piezo channel in a trigeminal nerve to directly modulate a trigeminal nerve mechanoreceptor, so that the flavor of the trigeminal nerve is improved. The activity of the Piezo channel is inhibited, so that the sensitivity of the Piezo channel to mechanical friction of aerosol particles is reduced, and the nasal cavity roughness is reduced. Meanwhile, the flavor modifier disclosed by the invention can also cooperate with olfactory signals transmitted by other components in the atomized essence to jointly improve the smoothness, the fineness and the overall moist feeling of the fragrance.

The application discloses a device for judging the decompression effect of intraoperative trigeminal neuralgia, and relates to the technical field of medical monitoring devices, comprising a forceps body, a collection probe is arranged at the tip of the forceps body, a wiring box is arranged on the side of the forceps body away from the collection probe, a distance adjusting mechanism and an auxiliary center positioning mechanism are arranged between the wiring box and the forceps body, the forceps body with adjustable spacing and the distance adjusting mechanism are arranged, the flexible adjustment of the spacing of the collection probe is achieved, the overall signal of the ganglion segment can be detected by increasing the spacing, the smaller nerve area can be focused by reducing the spacing, the signal difference under different spacings is compared, the compression point is accurately positioned, blind decompression is avoided, the auxiliary center positioning mechanism is arranged, the center point of the forceps body and the corresponding position of the collection probe are quickly positioned, the medical staff accurately aims at the trigeminal nerve to be detected, the positioning deviation is avoided, the collection signal is not inaccurate, the trigeminal neuralgia clustering neural network algorithm is combined, a visual distribution view is generated, and the accuracy of decompression effect judgment and the operation efficiency are improved.

The invention relates to the technical field of traditional Chinese medicines, relates to new application of a traditional Chinese medicine composition, and in particular relates to application of the traditional Chinese medicine composition in preparation of a medicine for preventing and / or treating migraine. The traditional Chinese medicine composition is prepared from cassia twig, white peony root, honey-fried licorice root, ginger, jujube, ginseng, Chinese angelica, salted morinda officinalis and dwarf lilyturf tuber. The traditional Chinese medicine composition provided by the invention can obviously reduce serum NO and trigeminal nervous tissue SP content of migraine rats, increase trigeminal nervous tissue DA content, obviously improve head and face pain threshold and brain tissue DA content of the migraine rats and reduce brain tissue PGE2 content, and has a good treatment effect on migraine.

In an illustrative embodiment, systems and methods for treating stress and / or for improving alertness in a subject using neurostimulation therapy include placing first electrode(s) on, over, or adjacent to an auricular branch of the vagus nerve, placing second electrode(s) on, over or adjacent to an auriculotemporal nerve, and delivering therapeutic stimulation pulses via the first electrode(s) and the second electrode(s) by delivering a first series of stimulation pulses to the first electrode(s), the first series configured to increase activity in neural medullary structure(s), and delivering a second series of stimulation pulses to the second electrode(s), the second series configured to increase activity in neural structures within the Trigeminocervical Complex.

The invention relates to a portable electrical stimulation device integrating vagus nerve-trigeminal nerve stimulation, and relates to the technical field of medical electrical stimulation equipment, the portable electrical stimulation device comprises a neck ring body, a heating electrical stimulation assembly and a main storage bag, the heating electrical stimulation assembly is arranged on the outer surface of the neck ring body, and the main storage bag is arranged at the bottom of the right side of the neck ring body. The auxiliary storage bag is arranged at the bottom of the left side of the neck ring body, the heating electrical stimulation assembly accurately corresponds to the three-fork two-type nerve branch area, the sleep state can be more comprehensively improved and sleep disorders can be relieved through cooperation of the heating electrical stimulation assembly and the three-fork two-type nerve branch area, blood circulation of a target area is promoted through synchronous heating, and the nerve excitation threshold value is reduced. According to the device, long-term nerve regulation and control can be better carried out by a user, a connecting cable is stored through the main storage bag and the auxiliary storage bag, the cable is prevented from being knotted or damaged due to extrusion, the arrangement time before use is shortened, and meanwhile, a magnetic attraction piece is utilized to attract a mounting piece of the heating electrical stimulation assembly, so that the whole device is more compact and regular when carried.

Provided are methods for treating trigeminal nerve pain in a subject in need thereof. The method may include administering to the subject by perineural injection of the trigeminal nerve a therapeutically effective amount of a composition comprising an alpha-2 adrenergic agonist, such as guanfacine. The composition may further comprise lidocaine.

Botulinum toxin for use in treating asthma in a patient in need thereof is provided. The treatment comprises administering botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous or intradermal injection. The subcutaneous or intradermal injection may be administered to and / or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, a sacral nerve, or a combination thereof of the patient.

In an illustrative embodiment, methods and systems for treating uterine bleeding include applying, at least every other day in which a subject exhibits or is expected to exhibit menstrual bleeding, neurostimulation therapy in one or more sessions, each session having a duration of at least five minutes, the neurostimulation therapy including applying electrical neurostimulation or mechanical neurostimulation to directly and / or indirectly activate one or more neural targets, the one or more neural targets including a trigeminal cervical complex and / or vagal efferent fibers. The neurostimulation therapy may be configured to enhance platelet function of the subject, thereby reducing a total volume of blood loss over a course of the menstrual bleeding.

This invention belongs to the field of biomedical technology and relates to... Follistatin ( Fst The application of genes in the prevention and treatment of trigeminal nerve injury-related oromofacial pain is disclosed in this invention. Fst FST expression was significantly upregulated in the trigeminal ganglion (TG) and the spinal trigeminal nucleus (Sp5). Overexpression of FST exacerbated orofacial pain, sensitivity, anxiety, and depression caused by trigeminal nerve injury. Based on this, the present invention provides... Fst Gene-targeting siRNA, shRNA, CRISPRCas9 gene editing systems, specific antibodies, or small molecule inhibitors are used to develop novel drugs for the treatment of orofacial neuropathic pain.

In some embodiments, disclosed herein are systems and methods of treating a patient that can include the steps of accessing the sphenopalatine fossa, and cannulating the inferior orbital fissure from the sphenopalatine fossa to access the retro-orbital space. The sphenopalatine fossa can be accessed via various routes, including percutaneously. Accessing the sphenopalatine fossa can include the step of inserting a needle-catheter system into the sphenopalatine fossa. Integrated needle-catheter systems as described herein can also be configured to access the trigeminal ganglion, epidural space, intrathecal space, and other desired anatomical locations.

A device for the transcutaneous electrical stimulation of the trigeminal nerve is provided. The device has an elongated symmetrical support with at least one electrode pair, and the support can be applied on a person's forehead in the supraorbital region to cover the afferent paths of the supratrochlear and supraorbital nerves of the ophthalmic branch of the trigeminal nerve. Each electrode pair contacts a self-adhesive conductive gel that at least partially covers one surface of the support for attaching the support to the forehead to be applied to two lateral zones with the exception of an insulating central zone. Each lateral zone has one electrode of the electrode pair, an electric circuit for supplying to the electrode pair electric pulses that have a predefined intensity, and a measurement means for measuring the intensity of the supplied pulses that is connected to the electric circuit.

In an illustrative embodiment, methods and systems for treating uterine bleeding include applying, at least every other day in which a subject exhibits or is expected to exhibit menstrual bleeding, neurostimulation therapy in one or more sessions, each session having a duration of at least five minutes, the neurostimulation therapy including applying electrical neurostimulation or mechanical neurostimulation to directly and / or indirectly activate one or more neural targets, the one or more neural targets including a trigeminal cervical complex and / or vagal efferent fibers. The neurostimulation therapy may be configured to enhance platelet function of the subject, thereby reducing a total volume of blood loss over a course of the menstrual bleeding.

The invention discloses siRNA (small interfering Ribonucleic Acid) targeting BACH1 and application of the siRNA in preparation of chronic pain treatment medicines, belongs to the field of biological medicines, and discloses a compound, a composition and a method for regulating BACH1 gene expression, regulating response of activity and regulating characters, diseases or conditions of a BACH1 gene expression pathway. A behavioral result shows that the group of siRNAs can significantly inhibit mechanical hyperalgesia generated by peripheral nerve injury induction; the siRNA is injected into the trigeminal ganglion of a neuropathic pain model mouse, molecular biology experiments show that the siRNA can remarkably reduce expression of BACH1 in the trigeminal ganglion of the mouse in vivo, a new target and a new method are provided for research and development of chronic pain treatment drugs, non-chemical modification and chemical modification nucleic acid molecules of the targeted BACH1 gene are provided, and the application prospect is wide. The traditional Chinese medicine composition has a good medicine effect on chronic pain, lays a foundation for medicine preparation for treating chronic pain, and has great application and popularization value.

Provided are methods for treating trigeminal nerve pain in a subject in need thereof. The method may include administering to the subject by perineural injection of the trigeminal nerve a therapeutically effective amount of a composition comprising an alpha-2 adrenergic agonist, such as guanfacine. The composition may further comprise lidocaine.

The application belongs to the technical field of animal model construction, and discloses a method for establishing a tumor-bearing animal model for an OCT system, wherein a SD rat supratentorial brain parenchymal glioma model, a SD rat chiasma glioma model and a SD rat brain stem glioma model are constructed by using a C6 cell line; a rat sciatic nerve sheath tumor model and a rat trigeminal nerve RT4 tumor model are constructed by using an RT4 cell line to obtain a SD rat RT4 tumor cell animal model; and a BALB / c nude mouse U87MG tumor cell animal model and a BALB / c nude mouse IOMM-Lee tumor cell animal model are constructed by using a U87MG cell line and an IOMM-Lee cell line, respectively. The application successfully constructs a rat brain glioma model, a chiasma glioma model, a trigeminal nerve sheath tumor model, a sciatic nerve sheath tumor model, a nude mouse brain glioma model and a nude mouse sciatic nerve meningioma model.

In an illustrative embodiment, systems and methods for treating stress and / or for improving alertness in a subject using neurostimulation therapy include placing first electrode(s) on, over, or adjacent to an auricular branch of the vagus nerve, placing second electrode(s) on, over or adjacent to an auriculotemporal nerve, and delivering therapeutic stimulation pulses via the first electrode(s) and the second electrode(s) by delivering a first series of stimulation pulses to the first electrode(s), the first series configured to increase activity in neural medullary structure(s), and delivering a second series of stimulation pulses to the second electrode(s), the second series configured to increase activity in neural structures within the Trigeminocervical Complex.

The invention belongs to the technical field of medicines, and particularly relates to a pharmaceutical composition for treating headache and a preparation method thereof. The pharmaceutical composition comprises the following raw materials in parts by weight: 30-40 parts of a pharmaceutical active component, 2-4 parts of a disintegrating agent, 6-11 parts of a filler and 0.2-0.5 part of a lubricant, the active pharmaceutical ingredient consists of porphyridium polysaccharide and manganese gluconate in a mass ratio of 1: (0.5-1). The action mechanisms of the two active components in the pharmaceutical composition are clear and complementary: porphyridium polysaccharide reduces the expression of a proinflammatory factor by inhibiting an NF-kappa B signal channel so as to relieve the stimulation to trigeminal nerve endings, and the porphyridium polysaccharide is mild in action and can avoid the potential influence of strong immunosuppression on the immune system of children; manganese gluconate blocks a CGRP receptor in a targeting manner, directly inhibits nerve ending sensitization and central pain signal transduction mediated by the pain-inducing peptide, and intervenes migraine attack from a key path.

The application discloses a pressure-measurable trigeminal nerve balloon device, and relates to the technical field of nerve treatment. The device comprises a connector and a syringe, one end of the connector is provided with a lead wire, one end of the lead wire penetrates through a catheter and extends to the outside of the catheter, the tail end of the lead wire is fixedly connected with a balloon body, and one end of the connector is fixedly connected with a connecting end. The device is provided with a three-way joint, a pressure gauge and a second threaded head, the outlet end of the syringe is inserted into the liquid end, then the piston column is pushed to move, the piston column divides the liquid in the syringe into two parts, and the two parts of the liquid are injected into the connector and the lead wire through the liquid end, the three-way joint, the second threaded head and the connecting end, then the liquid enters the balloon body through the lead wire, the balloon body is inflated to compress the trigeminal nerve, and the pressure in the balloon body can be detected through the pressure gauge, so that the dose of the injected developing liquid can be adjusted at any time.

A method of treating vertigo in a patient in need thereof comprises administering a botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous / intradermal injection. The subcutaneous / intradermal injection may be administered to and / or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and a sacral nerve of the patient.

An apparatus for use in delivering electrical stimulation to a trigeminal nerve of the mouth of a user, the apparatus comprising: a teeth engaging portion; at least one supporting member extending from the teeth engaging; and at least a first pair of electrodes comprising a first electrode and a second electrode, wherein the first electrode and the second electrode are supported by the at least one supporting member; and wherein the at least one supporting member, when the teeth engaging portion is engaged with teeth of the user, is configured to bias each electrode of the first pair of electrodes to contact tissue of a palate of the mouth of the user to deliver the electrical stimulation to the trigeminal nerve.

The invention discloses a nasal delivery double-chain RNA / Mn < 2 + > nano-drug as well as a preparation method and application thereof in immunotherapy. And adding the polymer into a solution containing double-stranded RNA and manganese salt, and self-assembling to form the nasal delivery double-stranded RNA / Mn < 2 + > nano-drug. The invention provides a new technical scheme for the barrier of the BBB. The nano delivery system has the advantages in the aspects of overcoming the BBB and improving the in-vivo biological distribution of the drug, and the surface of the nano carrier is modified with a ligand targeted to an endothelial cell overexpression receptor, such as ApoE peptide and the like, so that the drug can be delivered to penetrate through the BBB; a non-invasive nasal-brain delivery strategy becomes a new scheme for improving drug availability and reducing toxic and side effects, the drug can bypass BBB and rapidly enter brain parenchyma through olfactory bulb and trigeminal nerve conduction pathways, and an immune drug delivered by the nasal cavity can rapidly enter nasopharynx-related lymphatic tissue (NALT) and is transferred to CLN through a lymphatic network around the nasal cavity, so that the immune drug can be rapidly delivered to the nasopharynx-related lymphatic tissue (NALT). Further, a potent local immune response aiming at the in-situ GBM is induced.

The present invention relates to reducing an activation of a trigeminal ganglion neuron or cell and related uses in treating or preventing migraine.

This disclosure relates to a method, device, and system used for identifying and treating responders to external nerve stimulation via a combination of a skin electrode assembly and a functional near-infrared spectroscopy (fNIRS) device. More specifically, this specification discloses a method for cutaneous stimulation of the trigeminal nerve, occipital nerve, vagus nerve, facial nerve and / or any of their branches, and a method for measuring cerebral blood flow in a target brain region.

The present disclosure relates a novel method of improving motor learning by stimulating the trigeminal nerves and / or the occipital nerves. In particular implementations, the method of improving motor learning in a subject comprising stimulating the trigeminal nerves and / or the occipital nerves of the subject with electrical stimulation of 50-150 Hz or 1-5 kHz. The electrical current is administered as a biphasic symmetric square waveform in 30 s intervals.

Systems and methods are provided for combined ultrasound and electrical stimulation for treating inflammation, autoimmune disorders, rheumatoid arthritis, and the like. Noninvasive ultrasound stimulation may be applied to the spleen, joints, limbs, or a region experiencing pain that has local swelling, and electrical stimulation may be applied to the face, neck, or other body region to access a peripheral nerve, vagus nerve, trigeminal nerve, or other nerves in appropriately-timed patterns to drive therapeutic effects. Stimulation timings or delay timings may be optimized based upon a desired clinical effect or treatment. Multiple targets may be stimulated in a coordinated fashion to better mimic natural physiology. A wearable ultrasound phased array device may be used to beam form energy to target the spleen while also having imaging capabilities to track the motion of the spleen to maintain localized stimulation of target regions.

The present invention relates to reducing an activation of a trigeminal ganglion neuron or cell and related uses in treating or preventing migraine.

The invention relates to an edaravone oral instant film as well as a preparation method and application thereof, and belongs to the technical field of medicines. The invention relates to an edaravone oral instant film. The edaravone oral instant film is prepared from the following raw materials: edaravone, a film forming material and phospholipid, the phospholipid is one or more of soybean phospholipid, lecithin or hydrogenated soybean phospholipid, and the film-forming material is one or more of hydroxypropyl methyl cellulose, polyvinyl alcohol, polyethylene glycol or polyvinylpyrrolidone; the weight ratio of the edaravone to the film-forming material to the phospholipid is 1: (1-5): (1-5). The oral cavity instant film provided by the invention not only meets the requirement that the dissolution rate of the oral cavity instant film is greater than 30% under a non-leakage groove condition, but also can form nanoparticles which can remarkably penetrate through soft palate mucosa after meeting water, and is delivered into the brain through a trigeminal nerve path, so that the bioavailability and local drug concentration of edaravone are remarkably improved, and the oral cavity instant film is suitable for clinical application. Wide application prospects are realized in the application of treating nervous system diseases.